Cegedim Dendrite, the world's leading provider of life-sciences specific Customer Relationship Solutions (CRM), has signed a global SaaS (Software as a Service) CRM agreement with biopharmaceutical company UCB.
“It is exciting to support UCB in its patient-centric strategy. It proves the extended flexibility of the Cegedim Dendrite offering enables us to perfectly fit with new commercial models in the biopharmaceutical industry”
UCB is a global biopharmaceutical company dedicated to the research and development of innovative medicines for severe diseases in two therapeutic areas - central nervous system (CNS) and Immunology.
Beginning immediately, UCB will implement Cegedim Dendrite's flagship CRM solution, Mobile Intelligence™.
"It is exciting to support UCB in its patient-centric strategy. It proves the extended flexibility of the Cegedim Dendrite offering enables us to perfectly fit with new commercial models in the biopharmaceutical industry," said Laurent Labrune, Cegedim Dendrite CEO.
Mobile Intelligence™, available in SaaS single or multi-tenant, is the only biopharmaceutical specific CRM solution that can be scalable following a hierarchical model on a global, regional and national scale, to support international companies in building their CRM strategies around the world.
SOURCE Cegedim Dendrite
Precision unveiled: Exploring the cutting-edge of analytical weighing with Cubis® II ultra-high resolution balances